REHOVOT, Israel and NEW YORK, October 2 /PRNewswire-FirstCall/ --
- Management and Distinguished Scientists Will Provide Overview on Company's Diagnostic and Therapeutic Development Programs, as Well as on the microRNA Field
Rosetta Genomics, Ltd. (Nasdaq: ROSG), a global leader in microRNA-based diagnostics and therapeutics, announced today it will host its R&D Day on microRNAs and their significant potential in cancer treatment and other medical applications. This event will take place on Friday, October 26, from 12:00 pm-3:00 pm (New York time), and will be webcasted live on the "Investors" section of the company's website at http://www.rosettagenomics.com.
Amir Avniel, Chief Executive Officer of Rosetta Genomics, and Dalia Cohen, Ph.D., Executive Vice President, Global Head of Research & Development, will provide an overview of the company's development and commercialization plans for microRNA-based diagnostics and therapeutics, as well as its Intellectual Property.
In addition, the following leading scientific experts will provide their insights on microRNAs' future role in therapeutics and diagnostics:
Harvey Pass, MD, Professor and Chief, Division of Thoracic Surgery and Thoracic Oncology at NYU Medical Center.
Mahesh Mansukhani, MD, Associate Director of the Molecular Pathology Laboratory at Columbia University Medical Center
Prof. Moshe Hod, Director, Division of Maternal Fetal Medicine, Helen Schneider Hospital for Women, Rabin Medical Center
Eva M Hernando-Monge Ph.D., B.S., Assistant Professor, Department of Pathology, New York University School of Medicine
"As microRNAs are a relatively new fie
|SOURCE Rosetta Genomics Ltd|
Copyright©2007 PR Newswire.
All rights reserved